Eisai Co., Ltd. Annual Report 2001 - Eisai GmbH

More documents

Recommendations

Info

14 International Operations In the United States, fiscal 2000 brought the launch of several new competitors for Aricept and Aciphex. Nonetheless, sales of Aricept increased to ¥52.7 billion, as its advantages in terms of both efficacy and adverse event profile continued to distinguish it from other Alzheimer’s disease treatments. Sales of Aciphex rose sharply, to ¥44.0 billion, as customers continued to give high marks to the drug’s fast and consistent efficacy. During the period, we received approval from the U.S. Food and Drug Administration to manufacture Aciphex at our U.S. plant in North Carolina, and preparations are currently in progress to commence commercial production. In the current period, Eisai’s sales force will work to expand Aciphex's market share by using data to distinguish it from competitors. Our sales force also will use clinical research results and other data supporting the cost and efficacy advantages of Aricept to communicate the benefits of this important therapy to physicians, patients, and caregivers. We will also continue to seek approval for additional indications for both products to increase the benefits that they provide to patients. Stringent measures aimed at reducing health care expenditures contributed to harsh conditions in Europe in fiscal 2000. Despite a difficult environment, sales of Aricept rose 13.3% and sales of Pariet climbed 53.7%. Revenue results in Europe show that our European operations achieved profitability. We have reached our initial objective of establishing proprietary marketing bases in the United Kingdom, France and Germany and, in fiscal 2001, will concentrate on building market share for Aricept and Pariet by seeking approval for additional indications. All Eisai subsidiaries in Asia were profitable in fiscal 2000. During the period, we launched Pariet in Taiwan, Indonesia, Malaysia and Singapore. To reinforce our pharmaceutical operations in China, a particularly promising market, we liquidated the affiliate Shenyang Eisai Pharmaceutical Co., Ltd., and integrated operations at Eisai (Suzhou) Pharmaceutical Co., Ltd., a consolidated subsidiary. In fiscal 2001, we will focus on expanding market shares for mainstay prescription pharmaceuticals, notably Aricept, Pariet and the peripheral neuropathy treatment Methycobal, and on making these products available in more countries in the region. Eisai Annual Report 2001
Consumer Health Care Products The consumer health care products category encompasses a wide range of items sold over-the-counter (OTC) at drugstores and pharmacies in Japan, including medicated topical treatments. We continue to develop new, and modify existing, products in this category by gathering information on consumer needs from various sources, including our own customer hot line service. Many products in this category have been on the market for years and continue to enjoy solid support from consumers. These include the indigestion and heartburn treatment Saclon and the vitamin B2 preparation Chocola BB. We also develop and market OTC versions of prescription drugs such as Nabolin, an active B12 preparation. Sluggish consumer spending continued to inhibit growth in the market for consumer health care products in fiscal 2000. Nonetheless, sales in this category rose 4.0%, reflecting the launch of nine new products. New products introduced during the period include Chocola BB Fresh, a vitamin B2-enriched health drink sold in convenience stores and other new sales channels. Sales also grew for the vitamin B2 preparation Chocola BB Pure and Breathe Right nasal strips for nasal congestion relief, both of which enjoy particularly strong support from consumers. In line with our overall objective consumer health care products—which is to position Eisai as the brand of choice for consumers—we will continue to promote sales of products in the Chocola BB line. At the same time, we will work to ensure the early launch and rapid market penetration of new products. Eisai Annual Report 2001 15
Page 1 and 2: Human Health Care The script for ou
Page 3 and 4: CONSOLIDATED FINANCIAL HIGHLIGHTS E
Page 5 and 6: In Japan, we are proceeding with de
Page 7 and 8: Fiscal 2001 marks the conclusion of
Page 9 and 10: humanity-based sales activities the
Page 11 and 12: Selected Research Candidates (As of
Page 13 and 14: working together to develop antican
Page 15: REVIEW OF OPERATIONS PHARMACEUTICAL
Page 19 and 20: REINFORCING OUR RELATIONSHIP WITH S
Page 21 and 22: FINANCIAL SECTION Contents 20 Finan
Page 23: Net Income Current income taxes for
Page 26 and 27: 24 CONSOLIDATED FINANCIAL STATEMENT
Page 28 and 29: 26 Consolidated Statements of Incom
Page 30 and 31: 28 Consolidated Statements of Cash
Page 32 and 33: 30 (e) Property, plant and equipmen
Page 34 and 35: 32 Proceeds from sales of available
Page 36 and 37: 34 Note 7. Retirement and Pension P
Page 38 and 39: 36 III. Actual lease payments, Depr
Page 40 and 41: 38 Eisai Annual Report 2001 Million
Page 42 and 43: 40 JAPAN AND OVERSEAS OPERATIONS No
Page 44 and 45: 42 MAJOR PRODUCTS Prescription Phar
Page 46 and 47: 44 CORPORATE INFORMATION (As of Mar

Eisai Co., Ltd. Annual Report 2001 - Eisai GmbH

Create successful ePaper yourself

Delete template?

Save as template?